Literature DB >> 28358253

Comparison of Accelerated Corneal Collagen Cross-linking Types for Treating Keratoconus.

Yusuf Yıldırım1, Onur Olcucu2, Zehra Karaagac Gunaydin1, Alper Ağca1, Engin Bilge Ozgurhan1, Cengiz Alagoz1, Cagri Mutaf1, Ahmet Demirok3.   

Abstract

PURPOSE: To compare the results of different protocols for accelerated corneal collagen cross-linking (CXL) in patients with progressive keratoconus. MATERIALS AND
METHOD: This prospective comparative study involved 40 patients treated with intended UV-A radiance of 5.4 J/cm2 in 74 eyes (Group 1) and 42 patients treated with radiance of 7.2 J/cm2 in 72 eyes (Group 2). Visual acuity, subjective manifest refraction and corneal topography were analyzed before and 12 months after surgery in both groups. Postoperative complications were also noted. The results of the two protocols were statistically compared.
RESULTS: There were no statistically significant differences between the groups in uncorrected distance visual acuity, corrected distance visual acuity or corneal topography pre- or postoperatively. The differences in keratometric readings (K apex, SimK1 and SimK2) and refractive results were not significant.
CONCLUSION: The application of total intended UV-A radiance of 5.4 J/cm2 or 7.2 J/cm2 for accelerated CXL in patients with progressive keratoconus resulted in similar refractive and topographic outcomes.

Entities:  

Keywords:  Corneal collagen cross-linking; keratoconus; ultraviolet A

Mesh:

Substances:

Year:  2017        PMID: 28358253     DOI: 10.1080/02713683.2017.1284241

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  9 in total

1.  Complications of accelerated corneal collagen cross-linking: review of 2025 eyes.

Authors:  Semih Çakmak; Mehmet Emin Sucu; Yusuf Yildirim; Burcin Kepez Yildiz; Ahmet Kirgiz; Damla Leman Bektaşoğlu; Ahmet Demirok
Journal:  Int Ophthalmol       Date:  2020-07-26       Impact factor: 2.031

Review 2.  Current perspectives on corneal collagen crosslinking (CXL).

Authors:  Sandeepani K Subasinghe; Kelechi C Ogbuehi; George J Dias
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-04-06       Impact factor: 3.117

3.  Comparative Results of "Epi-Off" Conventional versus "Epi-Off" Accelerated Cross-Linking Procedure at 5-year Follow-Up.

Authors:  Cristina Ariadna Nicula; Dorin Nicula; Anca Maria Rednik; Adriana Elena Bulboacă
Journal:  J Ophthalmol       Date:  2020-07-22       Impact factor: 1.909

4.  Different accelerated corneal collagen cross-linking treatment modalities in progressive keratoconus.

Authors:  Ahmet Kirgiz; Mustafa Eliacik; Yusuf Yildirim
Journal:  Eye Vis (Lond)       Date:  2019-06-03

Review 5.  Keratoconus Treatment Algorithm.

Authors:  Konstantinos D Andreanos; Kate Hashemi; Myrsini Petrelli; Konstantinos Droutsas; Ilias Georgalas; George D Kymionis
Journal:  Ophthalmol Ther       Date:  2017-07-28

6.  Simultaneous Transepithelial Topography-Guided Photorefractive Keratectomy and Accelerated Cross-Linking in Keratoconus: 2-Year Follow-Up.

Authors:  Sibel Ahmet; Alper Ağca; Dilek Yaşa; Ahmet Alperen Koç; Mesut Toğaç; Yusuf Yıldırım; Burçin Kepez Yıldız; Ahmet Demirok
Journal:  Biomed Res Int       Date:  2018-10-15       Impact factor: 3.411

7.  Preliminary Characterization of Predictive Factors of the Visual Change after Epi-On and Epi-Off Corneal Collagen Crosslinking Techniques.

Authors:  Sidi Mohamed Hamida Abdelkader; Joaquín Fernández; Javier Sebastián; David P Piñero
Journal:  J Ophthalmol       Date:  2021-12-07       Impact factor: 1.909

8.  Accelerated versus conventional corneal collagen crosslinking: Short-term clinical outcomes in stabilizing keratoconus.

Authors:  Walaa Aldairi; Reham AlQahtani; Salem Alzaid; Ahmed Mousa; Rajiv Khandekar; Samar A Al-Swailem
Journal:  Saudi J Ophthalmol       Date:  2022-07-11

9.  Comparison of Two Different Accelerated Corneal Cross-linking Procedure Outcomes in Patients with Keratoconus

Authors:  Kemal Özülken; Gözde Aksoy Aydemir; Emre Aydemir; Hasan Kızıltoprak; Erdem Yüksel
Journal:  Balkan Med J       Date:  2020-01-07       Impact factor: 2.021

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.